2019

1. Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: Efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

   Breast Cancer: Targets and Therapy, Vol. 11, pp. 29-42